Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Oct

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Study Examines Use of External-Beam Radiotherapy as a Bridging Therapy for Patients With HCC Awaiting Transplant

Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer

FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer

Addition of Vincristine, Topotecan, and Cyclophosphamide to Five-Drug Interval-Compressed Chemotherapy for Ewing Sarcoma

Baseline Health-Related Quality of Life and Outcomes in Patients With Advanced Cancer